Search

Your search keyword '"Zargar‐Shoshtari, Kamran"' showing total 21 results
Start Over Author "Zargar‐Shoshtari, Kamran" Journal journal of urology
21 results on '"Zargar‐Shoshtari, Kamran"'

3. MP66-15 THE PROGNOSTIC VALUE OF NEUTROPHIL-LYMPHOCYTE RATIO FOR METASTATIC RENAL CELL CARCINOMA WITH VENOUS TUMOR THROMBUS PATIENTS UNDERGOING CYTOREDUCTIVE NEPHRECTOMY: A MULTI-INSTITUTION CONSORTIUM ANALYSIS

Author

Peyton, Charles, primary, Abel, Jason, additional, Chipollini, Juan, additional, Boulware, David, additional, Azizi, Mounsif, additional, Karam, Jose, additional, Margulis, Vitaly, additional, Master, Viraj, additional, Matin, Surena, additional, Raman, Jay, additional, Sexton, Wade, additional, Wood, Christopher, additional, Zargar-Shoshtari, Kamran, additional, and Spiess, Philippe, additional

Published
2018
Full Text
View/download PDF

4. Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus

Author

Abel, E. Jason, primary, Spiess, Philippe E., additional, Margulis, Vitaly, additional, Master, Viraj A., additional, Mann, Michael, additional, Zargar-Shoshtari, Kamran, additional, Borregales, Leonardo D., additional, Sexton, Wade J., additional, Patil, Datta, additional, Matin, Surena F., additional, Wood, Christopher G., additional, and Karam, Jose A., additional

Published
2017
Full Text
View/download PDF

5. MP58-04 DENSE DOSE MVAC VERSUS GC IN PATIENTS WITH CT3-4A BLADDER CANCER TREATED WITH RADICAL CYSTECTOMY: A REAL WORLD EXPERIENCE

Author

Zargar, Homayoun, primary, Shah, Jay B, additional, van de Putte, Elisabeth E Fransen, additional, Potvin, Kylea R., additional, Zargar-Shoshtari, Kamran, additional, van Rhijn, Bas W, additional, Daneshmand, Siamak, additional, Holzbeierlein, Jeff M, additional, Spiess, Philippe E, additional, Winquist, Eric, additional, Horenblas, Simon, additional, Dinney, Colin, additional, Fairey, Adrian S, additional, Kovac, Evan, additional, Krabbe, Laura-Maria, additional, Cookson, Michael S, additional, Jacobsen, Niels-Erik, additional, Gandhi, Nilay, additional, Griffin, Joshua, additional, Montgomery, Jeffrey S, additional, Vasdev, Nikhil, additional, Yu, Evan Y, additional, Xylinas, Evanguelos, additional, Campain, Nicholas J., additional, Seah, Jo-An, additional, Ercole, Cesar E, additional, Sridhar, Srikala S, additional, McGrath, John S, additional, Aning, Jonathan, additional, Shariat, Shahrokh F, additional, Wright, Jonathan L, additional, Thorpe, Andrew C, additional, Morgan, Todd M, additional, Grivas, Petros, additional, Stephenson, Andrew J, additional, Bivalacqua, Trinity J, additional, North, Scott, additional, Barocas, Daniel A, additional, Lotan, Yair, additional, Black, Peter C, additional, and Kassouf, Wassim, additional

Published
2017
Full Text
View/download PDF

6. MP58-03 DOSE DENSE MVAC PRIOR TO RADICAL CYSTECTOMY: A RETROSPECTIVE MULTI-INSTITUTIONAL EXPERIENCE

Author

Zargar, Homayoun, primary, Shah, Jay B, additional, van de Putte, Elisabeth E Fransen, additional, Potvin, Kylea R., additional, Zargar-Shoshtari, Kamran, additional, van Rhijn, Bas W, additional, Daneshmand, Siamak, additional, Holzbeierlein, Jeff M, additional, Spiess, Philippe E, additional, Winquist, Eric, additional, Horenblas, Simon, additional, Dinney, Colin, additional, Black, Peter C, additional, Kassouf, Wassim, additional, and Zargar, Homayoun, additional

Published
2017
Full Text
View/download PDF

8. MP49-15 CLINICAL ROLE OF ADDITIONAL ADJUVANT CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED UROTHELIAL CARCINOMA FOLLOWING NEOADJUVANT CHEMOTHERAPY AND CYSTECTOMY

Author

Zargar Shoshtari, Kamran, primary, Kongnyuy, Michael, additional, Sharma, Pranav, additional, Fishman, Mayer N, additional, Gilbert, Scott M., additional, Poch, Michael A, additional, Powsang, Julio M, additional, Spiess, Philippe E, additional, Zhang, Jingsong, additional, and Sexton, Wade J, additional

Published
2016
Full Text
View/download PDF

12. MP10-11 PELVIC EXTRANODAL EXTENSION LEADS TO WORSE OUTCOMES IN PENILE CANCER PATIENTS WITH POSITIVE PELVIC LYMPH NODES AND IS ASSOCIATED WITH A SURVIVAL BENEFIT AFTER ADJUVANT CHEMOTHERAPY: A MULTI-INSTITUTIONAL STUDY

Author

Sharma, Pranav, primary, Djajadiningrat, Rosa, additional, Zargar-Shoshtari, Kamran, additional, Catanzaro, Mario, additional, Zhu, Yao, additional, Nicolai, Nicola, additional, Horenblas, Simon, additional, and Spiess, Philippe, additional

Published
2015
Full Text
View/download PDF

13. PD41-05 FINAL PATHOLOGIC STAGE AFTER NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY FOR BLADDER CANCER: DOES PT0 PREDICT BETTER SURVIVAL THAN PTA/PTIS/PT1?

Author

Zargar, Homayoun, primary, Zargar-Shoshtari, Kamran, additional, Fairey, Adrian S., additional, Mertens, Laura S., additional, Dinney, Colin P., additional, Mir, Maria C., additional, Krabbe, Laura-Maria, additional, Cookson, Michael S., additional, Jacobsen, Niels-Erik, additional, Gandhi, Nilay, additional, Griffin, Joshua, additional, Montgomery, Jeffrey S., additional, Vasdev, Nikhil, additional, Yu, Evan Y., additional, Xylinas, Evanguelos, additional, Campain, Nicholas J., additional, Kassouf, Wassim, additional, Dall'Era, Marc A., additional, Seah, Jo-An, additional, Ercole, Cesar E., additional, Horenblas, Simon, additional, Sridhar, Srikala S., additional, McGrath, John S., additional, Aning, Jonathan, additional, Shariat, Shahrokh F., additional, Wright, Jonathan L., additional, Thorpe, Andrew C., additional, Morgan, Todd M., additional, Holzbeierlein, Jeff M., additional, Bivalacqua, Trinity J., additional, North, Scott, additional, Barocas, Daniel A., additional, Lotan, Yair, additional, Garcia, Jorge A., additional, Stephenson, Andrew J., additional, Shah, Jay B., additional, Van Rhijn, Bas W., additional, Daneshmand, Siamak, additional, Spiess, Philippe E., additional, and Black, Peter C., additional

Published
2015
Full Text
View/download PDF

14. MP50-02 IS FOLLOW UP BEYOND 2 YEARS NECESSARY FOR PT1A RENAL CELL CARCINOMA TREATED WITH NEPHRON SPARING SURGERY? AN ASSESSMENT OF LATE RECURRENCES AND SURVEILLANCE COSTS.

Author

Zargar-Shoshtari, Kamran, primary, Kim, Tim, additional, Simon, Ross, additional, Sharma, Pranav, additional, Yue, Binglin, additional, Lin, Hui-Yi, additional, Pow-Sang, Julio M., additional, Poch, Michael, additional, Spiess, Philippe E., additional, and Sexton, Wade J., additional

Published
2015
Full Text
View/download PDF

15. MP72-15 THE INTERVAL BETWEEN DIAGNOSIS AND RADICAL CYSTECTOMY DOES NOT IMPACT THE OUTCOMES OF PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY

Author

Xylinas, Evanguelos, primary, Zargar-Shoshtari, Kamran, additional, Shah, Jay, additional, Zargar, Homayoun, additional, Fairey, Adrian, additional, Mertens, Laura, additional, Mir, Maria, additional, Garcia, Jorge, additional, Stephenson, Andrew, additional, Krabbe, Laura-Maria, additional, Cookson, Michael, additional, Lotan, Yair, additional, Jacobsen, Niels-Erik, additional, Gandhi, Nilai, additional, Griffin, Joshua, additional, Montgomery, Jeffrey, additional, Vasdev, Nikhil, additional, Yu, Evan, additional, Campain, Nicholas, additional, Kassouf, Wassim, additional, Dall'Era, Marc, additional, Seah, Jo-An, additional, Ercole, Cesar, additional, Horenblas, Simon, additional, Sridhar, Srikala, additional, McGrath, Jonathan, additional, Aning, Jonathan, additional, Wright, Jonathan, additional, Thorpe, Andrew, additional, Morgan, Todd, additional, Holzbeierlein, Jeff, additional, Bivalacqua, Trinity, additional, North, Scott, additional, Barocas, Daniel, additional, Daneshmand, Siamak, additional, Van Rhijn, Bass, additional, Spiess, Philippe, additional, Dinney, Colin, additional, Black, Peter, additional, and Shariat, Shahrokh, additional

Published
2015
Full Text
View/download PDF

16. MP65-06 A MULTI-INSTITUTIONAL ANALYSIS OF OUTCOMES IN PATIENTS WITH CLINICALLY NODE POSITIVE UROTHELIAL BLADDER CANCER TREATED WITH INDUCTION CHEMOTHERAPY AND RADICAL CYSTECTOMY

Author

Zargar-Shoshtari, Kamran, primary, Zargar, Homayoun, additional, Fairey, Adrian S., additional, Mertens, Laura S., additional, Dinney, Colin P., additional, Mir, Maria C., additional, Krabbe, Laura-Maria, additional, Cookson, Michael S., additional, Jacobsen, Niels-Erik, additional, Gandhi, Nilay, additional, Griffin, Joshua, additional, Montgomery, Jeffrey S., additional, Vasdev, Nikhil, additional, Yu, Evan Y., additional, Xylinas, Evanguelos, additional, Campain, Nicholas J., additional, Kassouf, Wassim, additional, Dall'Era, Marc A., additional, Seah, Jo-An, additional, Sharma, Pranav, additional, Ercole, Cesar E., additional, Horenblas, Simon, additional, Sridhar, Srikala S., additional, McGrath, John S., additional, Aning, Jonathan, additional, Shariat, Shahrokh F., additional, Wright, Jonathan L., additional, Thorpe, Andrew C., additional, Morgan, Todd M., additional, Holzbeierlein, Jeff M., additional, Bivalacqua, Trinity J., additional, North, Scott, additional, Barocas, Daniel A., additional, Lotan, Yair, additional, Garcia, Jorge A., additional, Stephenson, Andrew J., additional, Shah, Jay B., additional, van Rhijn, Bas W., additional, Daneshmand, Siamak, additional, Spiess, Philippe E., additional, and Black, Peter, additional

Published
2015
Full Text
View/download PDF

17. PD31-09 CLINICAL FACTORS PREDICTING PATHOLOGICAL POSITIVE LYMPH NODES IN CLINICALLY NODE NEGATIVE PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY AND RADICAL CYSTECTOMY

Author

Zargar-Shoshtari, Kamran, primary, Zargar, Homayoun, additional, Dinney, Colin P, additional, Ercole, Cesar E, additional, Abdi, Hamidreza, additional, Kovac, Evan, additional, Garcia, Jorge A, additional, Stephenson, Andrew J, additional, Shah, Jay B, additional, Black, Peter, additional, and Spiess, Philippe E, additional

Published
2015
Full Text
View/download PDF

20. Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?

Author

Zargar, Homayoun, Zargar-Shoshtari, Kamran, Lotan, Yair, Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., and Black, Peter

Subjects
BLADDER cancer treatment, IMMUNOLOGICAL adjuvants, CANCER chemotherapy, CYSTECTOMY, MEDICAL centers
Abstract

Purpose We assessed survival dependent on pathological response after neoadjuvant chemotherapy in a large multicenter patient cohort, with a particular focus on the difference between the absence of residual cancer (pT0) and the presence of only nonmuscle invasive residual cancer (pTa, pTis, pT1). Materials and Methods We retrospectively reviewed records of patients with urothelial cancer who received neoadjuvant chemotherapy and underwent radical cystectomy at 19 contributing institutions from 2000 to 2013. Patients with cT2-4aN0M0 and eventual pN0 disease were selected for this analysis. Estimated overall survival was compared between patients with pT0 and pTa/Tis/T1 disease. A multivariable Cox proportional hazards regression model for overall survival was generated to evaluate hazard ratios for variables of interest. Results Of 1,543 patients treated with neoadjuvant chemotherapy and radical cystectomy during the study period 257 had pT0N0 and 207 had pTa/Tis/T1N0 disease. The Kaplan-Meier mean estimates of overall survival for pT0 and pTa/Tis/T1 cases were 186.7 months (95% CI 145.9–227.6, median 241.1) and 138 months (95% CI 118.2–157.8, median 187.4), respectively (p=0.58). In the Cox proportional hazards regression model for overall survival pTa/Tis/T1N0 status (HR 0.36, 95% CI 0.23–0.67) and pT0N0 status (HR 0.28, 95% CI 0.17–0.47) compared to pT2N0 pathology, positive surgical margin (HR 1.75, 95% CI 1.07–2.86), and receiving a methotrexate, vinblastine, doxorubicin and cisplatin regimen compared to an “other” regimen (HR 0.45, 95% CI 0.27–0.76) were predictors of overall survival. Conclusions pTa/Tis/T1N0 and pT0N0 stage on the final cystectomy specimen are strong predictors of survival in patients treated with neoadjuvant chemotherapy and radical cystectomy. We did not discern a statistically significant difference in overall survival when comparing these 2 end points. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

21. A Multi-Institutional Analysis of Outcomes of Patients with Clinically Node Positive Urothelial Bladder Cancer Treated with Induction Chemotherapy and Radical Cystectomy.

Author

Zargar-Shoshtari, Kamran, Zargar, Homayoun, Lotan, Yair, Shah, Jay B., van Rhijn, Bas W., Daneshmand, Siamak, Spiess, Philippe E., and Black, Peter C.

Subjects
MULTIHOSPITAL systems, HEALTH outcome assessment, BLADDER cancer patients, BLADDER cancer treatment, CANCER chemotherapy, CYSTECTOMY
Abstract

Purpose Selected patients with bladder cancer with pelvic lymphadenopathy (cN1-3) are treated with induction chemotherapy followed by radical cystectomy. However, the data on clinical outcomes in these patients are limited. In this study we assess pathological and survival outcomes in patients with cN1-3 disease treated with induction chemotherapy and radical cystectomy. Materials and Methods Data were collected on patients from 19 North American and European centers with cT1-4aN1-N3 urothelial carcinoma who received chemotherapy followed by radical cystectomy between 2000 and 2013. The primary end points were pathological complete (pT0N0) and partial (pT1N0 or less) response rates, with overall survival as a secondary end point. Logistic regression and Cox proportional hazard ratios were used for multivariate analysis of factors predicting these outcomes. Results The total of 304 patients had clinical evidence of lymph node involvement (cN1-N3). Methotrexate/vinblastine/doxorubicin/cisplatin was used in 128 (42%), gemcitabine/cisplatin in 132 (43%) and other regimens in 44 (15%) patients. The pN0 rate was 48% (cN1—56%, cN2—39%, cN3—39%, p=0.03). The complete and partial pathological response rates for the entire cohort were 14.5% and 27%, respectively. The estimated median overall survival time for the cohort was 22 months (IQR 8.0, 54). On Cox regression analysis overall survival was associated with pN0, negative surgical margins, removal of 15 or more pelvic nodes and cisplatin therapy. Conclusions Complete pathological nodal response can be achieved in a proportion of patients with cN1-3 disease receiving induction chemotherapy. The best survival outcomes are observed in male patients on cisplatin regimens with subsequent negative radical cystectomy margins and complete nodal response (pN0) with excision of 15 or more pelvic nodes. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results